Peptide Profile
Angiotensin (1-7)
Ang-(1-7) · Ang 1-7 · MasR agonist · ACE2 product
Angiotensin-(1-7) [Ang-(1-7)] is an endogenous heptapeptide hormone generated primarily through cleavage of angiotensin II by ACE2, functioning as a counter-regulatory arm of the renin-angiotensin system (RAS) by binding the Mas…
- Half-life
- ~9–10 sec (rat)
- Routes
- subcutaneous, intravenous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Angiotensin (1-7) is
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
Angiotensin-(1-7) [Ang-(1-7)] is an endogenous heptapeptide hormone generated primarily through cleavage of angiotensin II by ACE2, functioning as a counter-regulatory arm of the renin-angiotensin system (RAS) by binding the Mas receptor to promote vasodilation, anti-fibrotic, anti-inflammatory, and cardioprotective effects that oppose the vasoconstrictive actions of angiotensin II. Ang-(1-7) acts through the ACE2/Mas receptor axis to reduce oxidative stress, attenuate NF-kB-mediated inflammation, and suppress TGF-beta fibrosis signaling; the ACE2/Ang-(1-7)/Mas axis has emerged as a key regulatory pathway in cardiovascular and metabolic disease, and gained renewed research attention given ACE2's role as the SARS-CoV-2 entry receptor. A Phase 1-2 randomized clinical trial of Ang-(1-7) infusion in COVID-19 ICU patients reported preliminary safety, tolerability, and dose-response data, providing the primary indexed human pharmacokinetic evidence; broader cardiovascular protective applications are supported by preclinical data but have not been established by completed Phase 3 trials. Ang-(1-7) has no FDA approval and no approved therapeutic indication in any jurisdiction; it is an endogenous peptide under active clinical investigation as a candidate for cardiovascular, metabolic, and inflammatory conditions, with emerging human safety data but an incomplete evidence base for any specific approved clinical use.
Angiotensin (1-7) Benefits & Research Areas
Angiotensin (1-7) half-life calculator
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
What the evidence says about Angiotensin (1-7)
Research Evidence
based on 9 studies · 2 RCTs · most recent 2026
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Investigational
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
9 sources cited · 2 strong · 1 moderate · 6 weak
2 RCTs · 1 Case series · 1 Review · 5 Animals
Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study.
J Alzheimers Dis · 2026
Angiotensin-(1-7) improves oxygenation in mechanically ventilated COVID-19 patients: a randomized phase 1-2 seamless trial
Annals of Intensive Care · 2024
In a phase 1-2 seamless randomized trial of 107 mechanically ventilated COVID-19 patients, angiotensin-(1-7) 10 mcg/kg/day significantly increased oxygen-free days compared with controls (median 19 vs 14 days; p=0.04), supporting its role as a pulmonary protective and vasoactive agent in acute lung injury.
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Surgery: A Pilot Case Series.
Res Sq · 2026
# Summary Research found that Angiotensin-(1-7), a compound with neurovascular and anti-inflammatory properties, was feasible and well-tolerated when administered to older adults undergoing coronary artery bypass surgery, and showed preliminary signals of preserved cognitive function and reduced neuroaxonal injury markers compared to placebo. This pilot case series suggests that Angiotensin-(1-7) may warrant further investigation as a potential strategy to mitigate postoperative cognitive impairment following cardiac surgery.
Show 6 more sources ↓
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
Metabolites · 2026
# Summary Research found that Angiotensin (1-7) intervention in obese type 2 diabetic mice reduced blood glucose levels, decreased inflammatory markers, and improved lipid profiles while restoring pancreatic β-cell function. This study demonstrated that these metabolic improvements were associated with Angiotensin (1-7)'s regulatory effects on multiple pathways, including amino acid metabolism, lipid metabolism, insulin secretion, and cellular energy metabolism processes.
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Hypertension · 2026
# Summary Research found that acute severe hypertension induced by angiotensin II injection causes intravascular hemolysis, which increases prolyl endopeptidase (PEP) activity and decreases angiotensin-converting enzyme (ACE) activity in plasma. This study demonstrated that these hemolysis-related enzyme changes enhance the conversion of angiotensin II to angiotensin-(1-7) while reducing angiotensin II formation, potentially influencing acute blood pressure regulation mechanisms.
Differential Modulation of Spinal Angiotensin-Converting Enzymes Plays a Critical Role in the Development of Trigeminal Neuropathic Pain.
Pharmaceuticals (Basel) · 2026
# Summary Research found that nerve injury produces an imbalance in spinal angiotensin-converting enzymes, with increased ACE1 activity and decreased ACE2 activity in pain-processing regions of the spinal cord. This study demonstrated that restoring the ACE2 pathway and increasing angiotensin-(1-7) signaling through the Mas receptor reduced neuropathic pain in an animal model of trigeminal nerve injury, suggesting that modulating these enzyme systems may represent a novel therapeutic approach for chronic pain conditions.
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the renin-angiotensin system and inflammatory pathways.
Front Pharmacol · 2026
# Primary Finding Summary Research found that telmisartan exerted neuroprotective effects in an essential tremor model by increasing angiotensin (1-7) levels and MAS receptor expression in the cerebellum, which simultaneously reduced pro-inflammatory pathways and restored the balance between excitatory and inhibitory neurotransmitters. This study demonstrated that modulating the renin-angiotensin system toward its beneficial arm—characterized by elevated angiotensin (1-7) signaling—suppressed neuroinflammation and neurodegeneration associated with tremor symptoms.
Converting enzyme determines plasma clearance of angiotensin-(1-7)
Hypertension · 1998
Neurotherapeutic roles of the protective arm of the renin-angiotensin system: from inflammation to cognitive rescue.
Mol Biol Rep · 2026
Angiotensin (1-7) Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSAngiotensin (1-7)
Frequently Asked Questions — Angiotensin (1-7)
Angiotensin-(1-7) [Ang-(1-7)] is an endogenous heptapeptide hormone generated primarily through cleavage of angiotensin II by ACE2, functioning as a counter-regulatory arm of the renin-angiotensin system (RAS) by binding the Mas receptor to promote vasodilation, anti-fibrotic, anti-inflammatory, and cardioprotective effects that oppose the vasoconstrictive actions of angiotensin II. Ang-(1-7) acts through the ACE2/Mas receptor axis to reduce oxidative stress, attenuate NF-kB-mediated inflammation, and suppress TGF-beta fibrosis signaling; the ACE2/Ang-(1-7)/Mas axis has emerged as a key regulatory pathway in cardiovascular and metabolic disease, and gained renewed research attention given ACE2's role as the SARS-CoV-2 entry receptor.
cardiovascular protection, anti-fibrotic, vasodilation, insulin sensitivity, kidney protection.
Research on Angiotensin (1-7) primarily documents effects related to cardiovascular protection and anti-fibrotic and vasodilation and insulin sensitivity and kidney protection. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For Angiotensin (1-7), its FDA status is investigational (not FDA-approved), and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
In a phase 1-2 seamless randomized trial of 107 mechanically ventilated COVID-19 patients, angiotensin-(1-7) 10 mcg/kg/day significantly increased oxygen-free days compared with controls (median 19 vs 14 days; p=0.04), supporting its role as a pulmonary protective and vasoactive agent in acute lung injury.
How to get Angiotensin (1-7)
Where to buy Angiotensin (1-7)
Coverage expanding
No providers currently list Angiotensin (1-7). Get notified when one does, or explore providers carrying similar peptides in the Longevity category.
Questions to ask your provider
Stay updated on Angiotensin (1-7) providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.